Brenus Pharma announces first patients dosed in its first-in-human trial evaluating STC-1010, a next-generation immunotherapy
#AACR2025: Brenus Pharma presents late-breaking preclinical data on its “off-the-shelf” next-generation immunotherapy candidate, STC-1010, now moving to clinic
Brenus Pharma publishes promising proof of concept results of their therapeutic platform in the scientific Frontiers in Oncology journal
BIG BPI – Brenus Pharma took part in the roundtable “Biotherapies: What potential for technology platforms?”
BIO SPACE – Brenus Pharma Raises $25 Million to Accelerate Clinical Trials of Its Precision Anti-cancer immunotherapy
THE TIMES MAGAZINE – Brenus Pharma secures $25 million to propel clinical trials for precision anticancer immuotherapy
Brenus Pharma raises $25 million to accelerate clinical trials of its precision anticancer immunotherapy
